The Pancreatic Cancer Action Network Selects Oncolytics Biotech Inc. To Receive $5M Therapeutic Accelerator Award To Develop Leading-Edge Treatments
Portfolio Pulse from Benzinga Newsdesk
Oncolytics Biotech, Inc. (NASDAQ:ONCY) has been selected by the Pancreatic Cancer Action Network (PanCAN) to receive a $5 million Therapeutic Accelerator Award. The award is in recognition of Oncolytics' work on pelareorep, an investigational immunotherapy treatment for pancreatic cancer. The grant will fund the next stage of research, which includes a clinical trial of pelareorep in combination with modified FOLFIRINOX chemotherapy. If successful, the treatment may advance to late-stage clinical development through the PanCAN Precision Promise adaptive clinical trial platform.
September 26, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncolytics Biotech's receipt of the $5 million Therapeutic Accelerator Award from PanCAN could boost its research and development efforts, potentially leading to advancements in pancreatic cancer treatment. This could positively impact the company's stock in the short term.
The $5 million grant from PanCAN will enable Oncolytics Biotech to continue its research on pelareorep, a promising immunotherapy treatment for pancreatic cancer. If the clinical trials are successful, this could lead to advancements in pancreatic cancer treatment and potentially increase the company's stock value.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100